- Conditions
- Healthy Volunteers
- Interventions
- Ortho-Cyclen, Evacetrapib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 314
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Patient Preference
- Interventions
- Dexamethasone, Standard of care surgery
- Drug · Other
- Lead sponsor
- Ophthalmic Consultants of Long Island
- Other
- Eligibility
- 22 Years to 100 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Garden City, New York
- Conditions
- Clinical Pharmacology, Healthy Volunteer Study
- Interventions
- Placebo, Pomalidomide, Moxifloxacin
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Prolonged QTc Interval, Pharmacokinetic
- Interventions
- 100 μg cebranopadol, 200 μg cebranopadol, 400 μg cebranopadol, Placebo to cebranopadol encapsulated tablets, 400 mg Moxifloxacin, Placebo to moxifloxacin encapsulated tablets
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Healthy, Long QT Syndrome
- Interventions
- ERB-041
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Insulin Sensitivity, Cardiovascular Risk, Perimenopausal Disorder
- Interventions
- Ortho Cyclen®
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Healthy
- Interventions
- 1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin hydrochloride ophthalmic solution, 0.3% gatifloxacin ophthalmic solution
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- TTR Cardiomyopathy
- Interventions
- Period 1, Period 2, Period 3
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Epilepsy
- Interventions
- BIA 2-093, Moxifloxacin, Placebo
- Drug
- Lead sponsor
- Bial - Portela C S.A.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Miramar, Florida
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- GSK1265744, GSK1265744 matching placebo, Moxifloxacin
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Healthy
- Interventions
- ABBV-CLS-7262, Placebo, Moxifloxacin 400mg
- Drug
- Lead sponsor
- Calico Life Sciences LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Grayslake, Illinois
- Conditions
- Obstetric Labour, Premature
- Interventions
- Retosiban 100 mg, Retosiban 800 mg, Placebo, Moxifloxacin 400 mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
- Interventions
- GSK189075
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Tuberculosis
- Interventions
- Moxifloxacin, PA-824, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Retinal Detachment, Achilles Tendon, Aneurysm, Dissecting
- Interventions
- Oral Fluoroquinolones (FQ), Other Antibiotics, Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 117,911 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Titusville, New Jersey
- Conditions
- Healthy
- Interventions
- ANX-188 Therapeutic Dose, ANX-188 Supratherapeutic dose, Saline, Moxifloxacin
- Drug
- Lead sponsor
- Mast Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Appendicitis
- Interventions
- Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin, Appendectomy
- Drug · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,552 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 25
- States / cities
- Sylmar, California • Torrance, California • Aurora, Colorado + 14 more
- Conditions
- Skin Diseases, Infectious
- Interventions
- PTK 0796, linezolid, moxifloxacin
- Drug
- Lead sponsor
- Paratek Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 7
- States / cities
- Fountain Valley, California • La Mesa, California • Oceanside, California + 4 more
- Conditions
- Healthy
- Interventions
- MK-8527, Moxifloxacin, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Marlton, New Jersey
- Conditions
- Functional Dyspepsia
- Interventions
- YM443, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Healthy
- Interventions
- tigecycline, moxifloxacin, 100 mL 0.9% Sodium Chloride intravenous, placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Bacterial Infections, Eye Infections
- Interventions
- AzaSite (azithromycin ophthalmic solution), Vigamox (moxifloxacin hydrochloride ophthalmic solution)
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy
- Interventions
- MOA-728
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Healthy Subjects
- Interventions
- SKI-606, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Tacoma, Washington